PGMI-004A is a potent and selective PGAM1 inhibitor. Inhibition of PGAM1 by PGMI-004A results in increased 3-PG and decreased 2-PG levels in cancer cells, leading to significantly decreased glycolysis, PPP flux and biosynthesis, as well as attenuated cell proliferation and tumor growth. References: Warmoes MO, Locasale JW. Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochem Pharmacol. 2014 Nov 1;92(1):12-21. doi: 10.1016/j.bcp.2014.07.019. Review. PubMed PMID: 25093285; PubMed Central PMCID: PMC4254151.

纯度：≥98%

CAS：1313738-90-7